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Abstract: Background. Mendelian randomization (MR) uses genetic variants as instrumental vari-
ables to estimate the causal effect of risk exposures in epidemiology. Two-sample summary-data MR
that uses publicly available genome-wide association studies (GWAS) summary data have become a
popular design in practice. With the sample size of GWAS continuing to increase, it is now possible to
utilize genetic instruments that are only weakly associated with the exposure.
Methods. To maximize the statistical power of MR, we propose a genome-wide design where more
than a thousand genetic instruments are used. For the statistical analysis, we use an empirical partially
Bayes approach where instruments are weighted according to their true strength, thus weak instruments
bring less variation to the estimator. The final estimator is highly efficient in the presence of many weak
genetic instruments and is robust to balanced and/or sparse pleiotropy.
Results. We apply our method to estimate the causal effect of body mass index (BMI) and major blood
lipids on cardiovascular disease outcomes. Compared to previous MR studies, we obtain much more
precise causal effect estimates and substantially shorter confidence intervals. Some new and statistically
significant findings are: the estimated causal odds ratio of BMI on ischemic stroke is 1.19 (95% CI:
1.07–1.32, p-value ≤ 0.001); the estimated causal odds ratio of high-density lipoprotein cholesterol
(HDL-C) on coronary artery disease (CAD) is 0.78 (95% CI 0.73–0.84, p-value ≤ 0.001). However, the
estimated effect of HDL-C becomes substantially smaller and statistically non-significant when we only
use the strong instruments.
Conclusions. By employing a genome-wide design and robust statistical methods, the statistical power
of MR studies can be greatly improved. Our empirical results suggest that, even though the relationship
between HDL-C and CAD appears to be highly heterogeneous, it may be too soon to completely dismiss
the HDL hypothesis. Further investigations are needed to demystify the observational and genetic
associations between HDL-C and CAD.
Keywords: Conditional score, HDL hypothesis, Partially Bayes, Robust statistics, Spike-and-slab prior.
Key messages:
• We utilize common variants across the whole genome (typically over a thousand) as instrumental
1Address for correspondence: Department of Statistics, The Wharton School, University of Pennsylvania, Jon M.
Huntsman Hall, 3730 Walnut Street, Philadelphia, PA 19104-6340 USA. E-mail: qyzhao@wharton.upenn.edu. Nov.
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variables.
• We extend a previously proposed method—robust adjusted profile score—to account for the mea-
surement error in GWAS summary data and biases due to weak instruments. A new method—
empirical partially Bayes—is developed to increase the statistical power when some genetic in-
struments are strong but many are very weak. The estimator is robust to balanced and/or sparse
pleiotropy.
• Our new and more powerful analysis greatly improves the precision of the causal effect estimates
of BMI and blood lipids on cardiovascular disease outcomes.
• Code to replicate the results (including diagnostics) is available in the R package mr.raps (https:
//github.com/qingyuanzhao/mr.raps).
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1 Introduction
Mendelian randomization (MR) is a method of using genetic variation to infer the causal effect
of a modifiable risk exposure on disease outcome. Since MR can give unbiased estimates in the
presence of unmeasured confounding, it has become a widely used tool for epidemiologists and
health scientists [1]. A prominent example is the overwhelming evidence of a causal link between
low-density lipoprotein cholesterol (LDL-C) and coronary heart disease found by several MR studies
[2, 3, 4, 5], which is consistent with the results of earlier landmark clinical trials [6].
From a statistical perspective, MR is a special instance of instrumental variable (IV) methods [7,
8]. Compared to classical applications of the IV methods in economics [9] and health research [10],
the most distinctive feature of MR is the enormous number of candidate instruments. Potentially,
any one of the millions of single nucleotide polymorphisms (SNP) in the human genome can be
used as an IV as long as it satisfies the following three validity criteria [10]:
1. Relevance: the SNP must be associated with the risk exposure.
2. Effective random assignment: the SNP must be independent of any unmeasured confounder
that is a common cause of the exposure and outcome under investigation.
3. Exclusion restriction (ER): the SNP affects outcome only through the risk exposure.
Among the three criteria above, the ER assumption is most disputable for MR due to a widespread
phenomenon called pleiotropy [11, 12], a.k.a. multiple functions of genes. For example, there are
many SNPs that are associated with both LDL-C and high-density lipoproteins cholesterol (HDL-
C), thus their effects on cardiovascular outcomes are possibly mediated by both lipids. When these
SNPs are used as instruments in a MR analysis of HDL-C, the ER assumption is likely violated.
To alleviate these concerns, most existing MR studies [13, 14, 15] select a handful of genome-
wide significant SNPs that are associated with the exposure risk factor and then seek to justify
that the ER assumption is reasonable. This simple design is very transparent, but it has some
major limitations. First, a full justification of the ER assumption requires a deep understanding
of the causal mechanism of the genes and can be invalidated by new findings. For example, Katan
[16], an early exponent of MR, proposed to use polymorphic forms of the APOE gene to estimate
the causal effect of blood cholesterol on cancer. However, as Davey Smith and Ebrahim [17] later
argued, they may be invalid instruments due to pleiotropic effects on other biomarkers. Second,
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the statistical power of MR is substantially reduced when the vast majority of SNPs are excluded,
including a lot of known genetic variation of the exposure and the outcome (Figure 1).
Meanwhile, it is well known to econometricians and statisticians that weak IVs can still provide
valuable information, especially if there are a number of them [18, 19]. In a previous paper [20],
we found that using weakly significant SNPs can greatly increase the efficiency of MR studies. In a
different but related application, Bulik-Sullivan et al. [21] also found that a genome-wide analysis is
much more powerful than using just the significant SNPs to estimate the genetic correlation. Using
weak instruments also helps to test the presence of effect heterogeneity [22] and identify candidate
IVs that do not satisfy the ER assumption, and the causal effect can still be consistently estimated
when the invalid IVs are rare or the pleiotropic effects are balanced [20, 23, 24, 25].
In this paper, we will introduce two new strategies that can greatly increase the statistical
power of MR studies. The first innovation is a truly genome-wide design: unlike previous MR
studies including our earlier work [20], no threshold will be used in the selection phase (apart
from demanding the genetic instruments to be independent). Typically, about 1000 independent
genetic instruments will be used in a genome-wide MR study. Notice that a genetic variant is
considered to satisfy the first IV assumption (relevance) even if it does not causally modify the
exposure. The variant can be used as an IV if it is in linkage disequilibrium with a causal variant
and thus associated with the exposure [7]. The blueprint of genome-wide MR has been discussed
in the literature before [26, 27, 28], but it was not feasible until recently because most existing
summary-data MR methods are heavily biased by weak IVs.
Our second innovation is an estimator that adaptively assigns weights to the IVs according to
their strength. This method is based on a general empirical partially Bayes approach introduced
by Lindsay [29]. Our previous method of adjusting the profile score [20] can be viewed as a
special case of this approach using a predetermined flat prior. Both approaches yield consistent
and asymptotically normal estimators of the causal effect, but using an empirically estimated prior
can substantially increase the statistical power. The structure of the empirical partially Bayes
approach also motivates a new diagnostic plot and a hypothesis test that is useful to detect effect
heterogeneity according to instrument strength.
2 Genome-wide design
We will use a working example to illustrate the genome-wide MR design, where the goal is to
estimate the causal effect of body mass index (BMI) on the risk of CAD. Increased adiposity was
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found to increase the risk of CAD in several previous MR studies [30, 31, 32, 33]. In this paper
we use this example as a positive control to demonstrate how using weak instruments can greatly
improve the precision of MR.
Our two-sample summary-data MR design makes use of three non-overlapping GWAS:
1. Selection dataset: A GWAS for BMI in the Japanese population involving 173, 430 indi-
viduals [34];
2. Exposure dataset: A GWAS for BMI in the UK BioBank involving more than 350, 000
individuals [35];
3. Outcome dataset: A GWAS for CAD conducted by the CARDIoGRAMplusC4D consor-
tium of about 185, 000 cases and controls with genotype imputation using the 1000 Genomes
Project [36].
For each GWAS, the summary data are publicly available, which report the linear or logistic
regression coefficients and standard errors (typically following a meta-analysis) of all the genotyped
or imputed SNPs. The selection and exposure datasets are two non-overlapping GWAS for the
same (or similar) phenotypes. We recommend to reserve the GWAS with higher quality (e.g. larger
sample size, same population as the outcome dataset) for the exposure dataset. The quality of
the selection dataset is often less important with a genome-wide MR design.
After obtaining the GWAS summary datasets, we preprocess the data to select genetic in-
struments for the statistical analysis. We first remove SNPs that do not coappear in all three
datasets. Then we use the remaining selection dataset to find independent SNPs (distance ≥
10 megabase pairs, linkage disequilibrium R2 ≤ 0.001) that are most associated with BMI. This is
done in a greedy fashion using the linkage-disequilibrium (LD) clumping function in the PLINK
software [37]. Using independent SNPs makes the statistical analysis more convenient and is com-
mon in MR studies [15]. Suppose p SNPs are selected after LD clumping. Usually p is about 1000
after the described preprocessing; in our working example concerning BMI and CAD, p = 1119.
A typical summary-data MR dataset thus consists of 2p marginal genetic effect estimates
(linear/logistic regression coefficients) and their standard errors from the exposure and outcome
datasets:
• γˆj , j = 1, . . . , p are the genetic effects on the exposure (BMI). The standard errors are denoted
by σXj .
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• Γˆj , j = 1, . . . , p are the genetic effects on the outcome (CAD). The standard errors are denoted
by σY j .
The study design described above is usually called a two-sample summary-data MR study [38].
Here we want to emphasize that using a separate and non-overlapping dataset for SNP selection is
very important for the unbiasedness of the genetic effect estimates, thus eliminating any bias due to
“winner’s curse” [39]. A common misconception is that, when the same GWAS is used for selection
and to obtain γˆj , the “winner’s curse” could be avoided by only using genome-wide significant
SNPs. This is not true, because although these SNPs are most likely true hits, the estimated
genetic effects γˆj are still biased. As a consequence, the causal effect estimate is generally biased
towards zero [20].
Figure 1 shows the distribution of genetic signal strength measured by the squared l2 norm
‖γ‖2 = ∑pj=1 γ2j (for BMI) and ‖Γ‖2 (for CAD) as a function of the selection threshold. Throughout
the paper we use bold letters to indicate vectors. These quantities are closely related to the
genetically inherited phenotypic variance and can be unbiasedly estimated by
∑
j γˆ
2
j − σ2Xj and∑
j Γˆ
2
j − σ2Y j over the SNPs that pass the selection threshold. Compared to the conventional
analysis that only uses 44 genome-wide significant SNPs (p-value ≤ 5 × 10−8), the genome-wide
MR design using all the 1119 SNPs contains almost twice amount of genetic variation for BMI.
This observation suggests a great potential of increasing the statistical power of the MR analysis
by utilizing the weaker instruments.
3 Statistical model
Following our previous article [20], our main modeling assumptions are:
Assumption 1 (Measurement error model).
γˆ
Γˆ
 ∼ N

γ
Γ
 ,
ΣX 0
0 ΣY

 , ΣX = diag(σ2X1, . . . , σ2Xp), ΣY = diag(σ2Y 1, . . . , σ2Y p).
Assumption 2 (Pleiotropy model). We assume the causal effect β satisfies Γj ≈ βγj for most
j = 1, . . . , p. More specifically, let α = Γ − βγ. We assume αj is independent of γj and most
αj
ind∼ N(0, τ2) where τ2 is a small overdispersion parameter. A small proportion of the SNPs (say
5%) might deviate from this model and have very large |αj |.
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Figure 1: Distribution of signal strength in the genome-wide MR of Body Mass Index (BMI)
on Coronary Artery Disease (CAD) as a function of the selection p-value:
∑
SNP j pass threshold γ
2
j
and
∑
SNP j pass threshold Γ
2
j . See Section 5 below for more details of this dataset. Shaded region
in the main plot is 95% confidence interval of the estimated cumulative signal strength. The
dotted vertical line corresponds to the standard genome-wide significance threshold 5×10−8 in the
selection dataset.
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The normality and independence assumptions in Assumption 1 can be immediately justified by
the large sample size of GWAS, non-overlapping samples in the selection, exposure, and outcome
datasets, and independence of the SNPs [20]. We have also implicitly assumed that the standard
errors σXj , σY j , j = 1, . . . , p reported in the GWAS are well calibrated.
Assumption 2 presumes that for most SNPs, the genetic associations with the exposure and the
outcome approximately satisfy a pair-wise linear relationship, with the common slope parameter
being the causal effect β. When all the SNPs are valid IVs, the linear relationship Γ = βγ can
be derived through assuming the SNPs, exposure and outcome variables follow a linear structural
model [40]. This result can be extended to nonlinear structural models by assuming the per-SNP
effects are minuscule and the SNPs affect the exposure in a homogenous way [20]. When the
outcome variable is the binary disease status, β may be interpreted as a conservative estimate of
the causal log-odds-ratio [20].
In reality, many genetic variants may violate the ER assumption and have other pathways to
affect CAD. For example, a SNP selected for the MR study of HDL-C might also be associated with
LDL-C, so its genetic association with CAD includes both the causal effect of HDL-C (if any) and
LDL-C. Motivated by the exploratory analysis for the MR of adiposity on blood pressure in our
previous paper [20], the robust MR model in Assumption 2 considers two types of deviations from
the exact linear relationship Γ = βγ: 1. small and balanced pleiotropy represented by the random
effects model αj ∼ N(0, τ2); 2. idiosyncratic and large pleiotropy. The first kind of deviation is a
special case of the InSIDE (Instrument Strength Independent of Direct Effect) assumption [40, 41],
while the second is similar to the sparse invalid IV assumption [23]. We think it is crucial that the
statistical method of MR is robust to both kinds of pleiotropy.
As a remark, when the InSIDE assumption is not satisfied, the causal effect β cannot be
identified without further assumptions. In this case, the estimand of our statistical method below
is β plus (γTγ)−1γTα, the regression slope of α on γ.
Before diving into the details of our statistical methodology, we want to mention that an alter-
native approach to handle widespread pleiotropy is the multivariable MR [42, 43], where several
exposures are examined simultaneously. In the rest of this paper we will focus on the genome-wide
design for univariate MR and explore the multivariate extension in a forthcoming work.
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4 Statistical method
In our previous article [20], we proposed a robust estimator based on adjusting the profile score
function of β and τ2, in which the nuisance parameters γ are profiled out. Here we propose a new
method to eliminate the nuisance parameters γ based on an empirical partially Bayes approach
introduced by Lindsay [29]. The new method has a simple geometric interpretation and can further
increase the statistical power.
4.1 Empirical partially Bayes
We first consider the simplest scenario: α = 0. The key insight is gained from deriving the
contribution of the j-th SNP to the conditional score function (Appendix A):
Cj(β, γj) =
γj(Γˆj − βγˆj)
β2σ2Xj + σ
2
Y j
.
It is straightforward to verify that the maximum likelihood estimator (MLE) of γj given β, denoted
as γˆj,MLE(β), is a sufficient statistic of γj and is independent of Γˆj − βγˆj . The decoupling of
“instrument strength” γj and “regression residual” Γˆj − βγˆj in Cj(β, γj) motivates us to consider
a general class of estimating functions:
C(β) =
p∑
j=1
fj(β, γˆj,MLE(β)) · ψ(tj(β))√
β2σ2Xj + σ
2
Y j
, tj(β) =
Γˆj − βγˆj√
β2σ2Xj + σ
2
Y j
,
where fj is an arbitrary function of β and γˆj,MLE, and ψ is an odd function (so ψ(−t) = −ψ(t)).
Because γˆj,MLE(β) is independent of Γˆj−βγˆj (and thus tj(β)), it is easy to show that E[C(β)] = 0 at
the true β. Therefore the root of C(β), denoted by βˆ, is a reasonable estimator of β. Geometrically,
this estimating function finds the β such that a transformation (by f) of the estimated “instrument
strength” γˆj,MLE(β) is uncorrelated with a transformation (by ψ) of the “regression residual” Γˆj −
βγˆj .
Different choices of the weighting scheme fj do not change the unbiasedness of C(β), but may
affect the statistical efficiency. The profile score developed in our previous article [20] amounts to
using γˆj,MLE(β) as the weight. To maximize statistical power, Lindsay [29] suggested to use the
empirical Bayes estimate of γj as the weight,
fj(β, γˆj,MLE(β)) = γˆj,EB(β) = Epiηˆ
[
γj |γˆj,MLE(β)
]
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where piη is a prior distribution of γ and ηˆ is an empirical estimate of the prior parameter. In-
tuitively, γˆj,EB shrinks γˆj,MLE towards 0. The function ψ is chosen to limit the influence of large
outliers (Section 4.3).
4.2 Spike-and-slab prior
In principle, a good choice of the prior distribution piη should have the following properties: 1.
the parametric family piη should fit the distribution of γ reasonably well, so we can gain efficiency
by using the empirical partially Bayes estimator; 2. The empirical Bayes estimator of γj should
be easy to compute since it will be evaluated many times when iteratively solving the estimating
equations. For these reasons, we choose to use a spike-and-slab Gaussian mixture prior [44, 45] to
model γj/σXj in all our empirical examples:
γj/σXj ∼ pip1,σ1,σ2 = p1 ·N(0, σ21) + (1− p1) ·N(0, σ22).
We decide to model the effect sizes γj/σXj instead of the effects γj because this scale is more
familiar and the shrinkage rule is easier to interpret. Typically, p1 is close to 1, σ
2
1 is close to
zero (the spike component), and σ22 is much larger than σ
2
1 (the slab component). The selective
shrinkage offered by the spike-and-slab prior [46] is essential to gain efficiency in empirical partially
Bayes (Appendix A.2).
4.3 Robust estimator
To account for invalid IVs in Assumption 2, we need to further estimate the overdispersion param-
eter τ2 = Var(αj) while being robust to large outliers of αj . Intuitively, we need two estimating
equations after eliminating the nuisance γ: one for β and one for τ2. For β, we can follow the
empirical partially Bayes approach described above by replacing σ2Y j with σ
2
Y j + τ
2. For τ2, we
need to adjust the profile score function of τ2 due to a Neyman-Scott phenomenon [20, 47]. To be
robust against outliers, we propose to use a bounded function of the “regression residual” Γˆj−βγˆj .
Next we describe the robust estimating function of β and τ2. Derivation of these functions is
very similar to our previous RAPS (Robust Adjusted Profile Score) approach [20] and the details are
omitted. Let ψ1(·) and ψ2(·) be two differentiable odd functions. The empirical partially Bayes ver-
sion of the RAPS estimator (βˆ, τˆ2) is given by the solution to C˜(β, τ2) = (C˜1(β, τ
2), C˜2(β, τ
2))T =
10
0, where
C˜1(β, τ
2) =
p∑
j=1
γˆj,EB(β, τ
2) · ψ1
(
tj(β, τ
2)
)
sj(β, τ2)
, and
C˜2(β, τ
2) =
p∑
j=1
ψ2
(
tj(β, τ
2)
)− δ
s2j (β, τ
2)
, where δ = E[ψ2(Z)] for Z ∼ N(0, 1),
where tj(β, τ
2) = (Γˆj − βγˆj)/sj(β, τ2) is the standardized regression residual and sj(β, τ2) =√
β2σ2Xj + σ
2
Y j + τ
2.
In the empirical examples below, we will use ψ2(t) = t · ψ1(t) and consider two choices of ψ1:
the non-robust identity function ψI and the robust Huber’s score function ψH . A situation we
sometimes encounter with real data is that the RAPS estimating equation may have several roots.
In this case, we report the root closest to the optimization-based profile-likelihood estimator if
there no other close root; otherwise we simply report the empirical partially Bayes estimator is not
available. We do not interpret this as a defect of the proposed method; rather, there is often strong
evidence for effect heterogeneity in this situation and we think the investigator should avoid making
any hasty conclusion. Further implementation details including how to compute the standard error
of βˆ can be found in Appendix A.2.
4.4 Diagnostics
A potential concern of using many weak instruments is that they might have more pleiotropy
than strong instruments [12, 48]. It is possible that the covariance Cov(αj , γj) is a function of
the instrument strength γj and is non-zero for certain range of γj (under Assumption 2 or more
generally the InSIDE assumption, Cov(αj , γj) ≈ 0). In general, the conclusions of a genome-wide
MR study are stronger if the weak instruments and strong instruments produce similar estimates
of the causal effect. We propose a simple diagnostic plot for this purpose, where the standardized
regression residual tj(β, τ
2) is plotted against (a standardized version of) the estimated instrument
strength
γˆj,EB(β, τ
2)
/√
Var
(
γˆj,EB(β, τ2)
)
,
evaluated at (β, τ2) = (βˆ, τˆ2). At the true value of (β, τ2) and when our modeling assumptions are
satisfied, tj should be independent of γˆj,EB and follow a standard normal distribution (possibly with
some outliers). This proposition can be empirically checked in a diagnostic plot (Appendices A.2.5
11
and C.2). Furthermore, it can used to test for the heterogeneity of the instruments. In our empirical
studies, we report the heterogeneity p-value as the null test for the linear regression of standardized
residuals on estimated instrument strength (expanded using B-splines with degrees of freedom
equal to p/20). This can be used as a falsification test of our modeling assumptions. A related
but different graphical outlier detection method is the radial MR plot proposed by Bowden et al.
(2018) [49].
5 Datasets
Table 1a summarizes the datasets used in our empirical studies. We will consider 6 phenotypes:
BMI, LDL-C, HDL-C, triglycerides (TG), CAD (or myocardial infarction), and ischemic stroke
(IS), and apart from IS, all other phenotypes have at least two non-overlapping GWAS results.
Table 1b lists the design of the empirical examples in the next two sections.
In our genome-wide MR design, we require the selection, exposure, and outcome GWAS to
have non-overlapping samples. Often the GWAS summary results are based on meta analyses of
smaller cohorts, so this assumption can be examined by checking if they have no common partici-
pating cohort. This is the case for most of our empirical examples below. The only exception is the
MR analysis of the blood lipids and CAD, where the outcome dataset obtained from the CAR-
DIoGRAMplusC4D consortium overlaps with the lipids GWAS reported by the GLGC consortium.
Nevertheless, the sample overlap appears to be small by examining the participating cohorts.
The amount of sample overlap can also be tested by running the LD score regression [55]. Bulik-
Sullivan et al. (2015) [21] show that the intercept in the LD score regression is proportional to the
amount of sample overlap, and the slope in the regression is proportional to the genetic correlation.
Figure 2 shows the results of the LD score regression for the datasets used in this paper. The
regression intercepts between the lipids datasets and CAD are relatively small and not statistically
significant, indicating the amount of sample overlap may be small.
6 Validation studies
6.1 Simulations
We perform two validation studies of the proposed statistical method. The first is a simulation study
that mimics the real data analysis for LDL-C and CAD using restricted instruments (Table C3a).
The GWAS summary data are simulated according to Assumptions 1 and 2 in six settings: NOO
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Phenotype Dataset name Citation or data source Population Sample size
BMI
BMI (Jap) Akiyama et al. (2017) [34] Asian 173,430
BMI (UKB) UK BioBank [35] European > 350, 000
Lipids
LDL (2010)
Teslovich et al. (2010) [50] European ∼ 100, 000HDL (2010)
TG (2010)
LDL (2013)
HDL (2013)
TG (2013)
Global Lipids Genetics
Consortium (2013) [51]
European ∼ 100, 000
CAD
CARDIoGRAM Schunkert et al. (2011) [52] European 86,995
C4D
C4D Genetics
Consortium (2011) [53]
European and
South Asian
30,442
CAD
CARDIoGRAMplusC4D
Consortium (2015) [36]
European ∼ 185, 000
Myocardial
Infarction
MI (UKB) UK BioBank [35] European > 350, 000
Ischemic
Stroke
IS Malik et al. (2018) [54] European 446,696
(a) List of publicly available GWAS summary datasets used in this paper. See Appendix B for web links we
used to download the datasets.
Study name
Screening
dataset
Exposure
dataset
Outcome
dataset
Results
Simulations
Data are simulated to mimic the MR
analysis for the LDL-CAD study below.
Section 6.1; Table 2
CAD-CAD MI (UKB) C4D CARDIoGRAM Section 6.2; Table 3
BMI-CAD
BMI (Jap) BMI (UKB)
CAD Section 7.1; Tables 4 and C1;
Figures 3 and C1BMI-IS IS
LDL-CAD LDL (2010) LDL (2013)
CAD
Section 7.2; Tables 5, C2 and C4;
Figures 3, C2 and C3
HDL-CAD HDL (2010) HDL (2013)
TG-CAD TG (2010) TG (2013)
LDL-MI LDL (2010) LDL (2013)
MI (UKB)
Section 7.2; Tables 5, C3 and C5;
Figures C4 and C5
HDL-MI HDL (2010) HDL (2013)
TG-MI TG (2010) TG (2013)
(b) List of MR analyses.
Table 1: GWAS Datasets and MR analyses in this paper.
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Figure 2: Results of LD score regression for the GWAS datasets. Significant intercepts and slopes
(adjusted for multiple testing) are indicated by asterisks.
(No Outlier), ALL (All SNPs), STR (Strong SNPs), WKS (Weak SNPs), NUL (null causal effect),
and EXP (exponetially distributed γ). The true causal effect β is set to 0.2 in all settings beside
NUL (where β = 0). This is smaller than the estimated causal effect of LDL-C so that the statistical
power is not always 100%. Except for EXP, the effect sizes γj/σXj , j = 1, . . . , p are generated from
the Gaussian mixture distribution with
Settings NOO, ALL, NUL p = 898, p1 = 0.92, σ1 = 0.47, σ2 = 3.48, resembling the analysis of
LDL-C using all the 898 SNPs.
Setting STR p = 11, p1 = 0.01, σ1 = σ2 = 5.93, resembling the analysis using the 11 SNPs that
are genome-wide significant in the selection dataset.
Setting WKS p = 887, p1 = 0.92, σ1 = 0.44, σ2 = 2.39, resembling the analysis using the 887
SNPs that are not significant in the selection dataset.
In setting EXP, the effect sizes are generated from the Laplace distribution with rate 1.5 (i.e. mean
absolute value is 2/3).
Next, Γ is generated by Γj = βγj + αj where αj is an independent Gaussian variable with
mean 0 and variance 3.8 × 10−5, the estimated τ2 in the LDL-CAD study using all 898 SNPs. In
settings ALL, STR, and WKS, we include an outlier (substract 5τ from the αj corresponding to
the strongest SNP) to test the method’s robustness to large idiosyncratic pleiotropy. Finally, the
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standard deviations (σXj , σY j) are the same as the standard errors in the analysis of LDL-C.
Setting
(# SNPs, Outlier)
Metric
Method
MR-Egger
MR-Egger
Wtd. Med.
RAPS RAPS
(SIMEX) (MLE) (Shrinkage)
NOO (898 SNPs, 0 outlier) Mean 0.13 0.15 0.12 0.20 0.20
RMSE 0.088 0.073 0.095 0.073 0.063
Coverage 61.1% 80.0% 74.2% 94.4% 95.3%
Power 78.6% 86.2% 56.3% 80.2% 88.9%
ALL (898 SNPs, 1 outlier) Mean 0.11 0.13 0.10 0.18 0.17
RMSE 0.105 0.089 0.117 0.082 0.073
Coverage 47.4% 65.8% 60.2% 91.8% 90.7%
Power 64.8% 74.9% 40.2% 71.1% 79.1%
STR (11 SNPs, 1 outlier) Mean 0.08 0.09 0.11 0.12 0.12
RMSE 0.237 0.163 0.167 0.144 0.145
Coverage 85.9% 81.1% 81.4% 84.9% 84.7%
Power 12.2% 20.5% 27.3% 26.0% 26.0%
WKS (887 SNPs, 1 outlier) Mean 0.08 0.10 0.07 0.18 0.17
RMSE 0.134 0.116 0.144 0.119 0.106
Coverage 38.3% 57.6% 50.6% 94.1% 92.6%
Power 33.6% 46.4% 19.1% 39.4% 44.9%
NUL (898 SNPs, 0 outlier) Mean 0.00 0.00 0.00 0.00 -0.00
RMSE 0.045 0.053 0.054 0.074 0.065
Coverage 93.7% 92.5% 95.9% 93.6% 94.1%
Power 6.3% 7.5% 4.1% 6.4% 5.9%
EXP (898 SNPs, 0 outlier) Mean 0.10 0.11 0.08 0.20 0.20
RMSE 0.112 0.111 0.135 0.085 0.082
Coverage 50.7% 65.7% 45.8% 94.3% 95.2%
Power 54.7% 50.7% 22.4% 69.9% 70.5%
Table 2: Simulation results using 1000 replications in 6 settings: NOO (no outlier), ALL (all SNPs),
STR (strong SNPs), WKS (weak SNPs), NUL (null causal effect), EXP (exponentially distributed
effect sizes). For each estimator we report four metrics: mean of βˆ (the true β = 0 in scenario
NUL and β = 0.2 in all other cases), root-mean-squared error (RMSE), coverage of the 95% CI,
and statistical power (proportion of 95% CI not covering 0).
Table 2 shows the results of this simulation study for five estimators: MR-Egger [41], MR-
Egger with SIMEX correction [56], weighted median [24], RAPS with MLE weights, and RAPS
with shrinkage weights (both RAPS estimator use the Huber score function as ψ). In settings with
no outlier (NOO, NUL, EXP), the RAPS estimators are unbiased and have the correct confidence
interval coverage. This shows that our empirical partially Bayes approach remains unbiased even
if the effect size distributions are misspecified. The SIMEX correction helps to reduce the weak
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psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 1650 5 1645
p1 0.99 0.01 0.88
σ1 0.44 1.58 0.25
σ2 4.5 6.96 1.25
MR-Egger 0.353 (0.033) 0.744 (0.476) 0.274 (0.034)
MR-Egger (SIMEX) 0.744 (0.054) 0.764 (0.559) 0.592 (0.057)
Wtd. Med. 0.127 (0.035) 0.664 (0.125) 0.089 (0.034)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0, ψI 1.029 (0.081) 1.042 (0.076) 0.937 (0.098) 0.936 (0.098) 1.058 (0.106) 1.147 (0.104)
τ2 = 0, ψH 1.058 (0.085) 1.097 (0.08) 0.822 (0.096) 0.821 (0.096) 1.076 (0.112) 1.178 (0.109)
τ2 6= 0, ψI 1.029 (0.081) 1.042 (0.076) 0.952 (0.178) 0.952 (0.178) 1.058 (0.106) 1.147 (0.104)
τ2 6= 0, ψH 1.055 (0.133) 1.096 (0.107) 0.926 (0.193) 0.926 (0.193) 1.076 (0.112) 1.178 (0.109)
Table 3: Validation CAD-CAD study: both the exposure and the outcome are coronary artery
disease, so the true β should be about 1. Our estimators are roughly unbiased and the shrinkage
estimator is about 10% more efficient when all SNPs are used.
instrument bias of MR-Egger but does not completely eliminate it. In other settings with a large
outlier (ALL, STR, WKS), the two RAPS estimators have much smaller bias and are generally much
more precise than the other methods. Among the two RAPS estimator, the one with shrinkage
weights is about 7.5% more efficient in setting EXP and about 25% more efficient in settings NOO,
ALL and WKS where the “spike” and the “slab” have greater disparity.
6.2 CAD-CAD study
Our second validation study uses a design in our previous article [20] where the “causal effect” β
can be regarded as known. In this example, all three datasets—selection, exposure, outcome
(as explained in Section 2)—are GWAS of coronary artery disease. In particular, MI (UKB) is used
to select SNPs, while C4D and CARDIoGRAM are used as the exposure and outcome datasets. Since
the exposure and outcome are the same variable, it is expected that γ and Γ in our model are the
same (or almost equal). Thus β ≈ 1 and τ2 ≈ 0.
In Table 3 we apply our statistical methods to this validation dataset in three ways: using all the
SNPs, using SNPs that are genome-wide significant in MI (UKB) (p-value ≤ 5 × 10−8), and using
SNPs that are not genome-wide significant in MI (UKB). In all cases the RAPS point estimates
are close to the truth β = 1. When only the strong instruments are used so there is virtually
no shrinkage, the shrinkage estimators are essentially the same as the non-shrinkage estimators.
When all the SNPs are used, the shrinkage estimators are about 10% more efficient. MR-Egger and
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Figure 3: Overview of the MR results for the effect of BMI and blood lipids on cardiovascular
diseases.
weighted median are heavily biased by the weak instruments in the CAD-CAD study. The SIMEX
correction [56] reduces but does not eliminate the bias of MR-Egger.
7 Application to the effect of BMI and blood lipids on cardiovascular diseases
We apply our method to estimate the causal effect of BMI and blood lipids on cardiovascular
disease outcomes. Figure 3 summarizes the main results and Tables 4 and 5 contain more details. By
default, we use the RAPS estimator with shrinkage weights, overdispersion adjustment and Huber’s
score function. In Tables C1 to C5 in the Appendix, we report the results using different sets of
instruments and different MR methods (including different specifications of our RAPS estimator).
7.1 Body Mass Index (BMI)
For the BMI studies we use the BMI (Jap) to select instruments and the BMI (UKB) to obtain the
SNP-exposure effects. We consider two outcomes, coronary artery disease (CAD) and ischemic
stroke (IS), using two GWAS summary datasets, CAD and IS, as described in Table 1. The results
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Outcome: CAD Outcome: IS
Previous MR studies for BMI
Holmes et al. (2014) [30]∗ (14 SNPs) 1.05 (0.75, 1.42) 1.15 (0.79, 1.68)
Ha¨gg et al. (2015) [31] (32 SNPs) 1.13 (0.70, 1.84) 1.83 (1.05, 3.20)
Dale et al. (2017) [32] (97 SNPs) 1.36 (1.22, 1.52) 1.09 (0.93, 1.28)
Lyall et al. (2017) [33] (93 SNPs) 1.35 (1.09, 1.69) 1.02 (0.71, 1.46)
New MR analysis for BMI
MR-RAPS
Using 44 significant SNPs 1.39 (1.11, 1.75) 1.19 (1.02, 1.4)
Using 1075 non-significant SNPs 1.53 (1.28, 1.83) 1.18 (1.03, 1.36)
Using all 1119 SNPs 1.47 (1.29, 1.68) 1.19 (1.07, 1.32)
p-value for heterogeneity 0.79 0.78
MR-Egger
Using 44 significant SNPs 1.67 (1.16, 2.40) 1.21 (0.95, 1.54)
Using 1075 non-significant SNPs 1.56 (1.27, 1.91) 1.11 (0.95, 1.28)
Using all 1119 SNPs 1.47 (1.26, 1.71) 1.14 (1.02, 1.27)
Wtd. Med.
Using 44 significant SNPs 1.32 (1.02, 1.70) 1.12 (0.91, 1.38)
Using 1075 non-significant SNPs 1.42 (1.15, 1.75) 1.23 (1.03, 1.46)
Using all 1119 SNPs 1.33 (1.09, 1.62) 1.12 (0.94, 1.32)
Table 4: Previous and new results of the effect of Body Mass Index (BMI) on coronary artery
disease. Statistically non-significant results are shown in blue color.
∗ The original results were reported per 1 kg/m2 of increase in BMI. We transformed the results
to per 1 SD increase of BMI using SD(BMI) = 4.6 kg/m2.
of the BMI studies are reported in Table 4. In summary we find strong evidence that BMI causally
increases the risk of CAD and IS and the estimated effects remain stable regardless of the instrument
strength. For CAD, in our most powerful analysis using all the instruments, the estimated odds
ratio is 1.47 (95% CI 1.29–1.68, p-value < 10−7). Using the non-significant SNPs reduces the
length of the CI by about 40%. For IS, the corresponding result is 1.19 (95% CI 1.07–1.32, p-value
= 0.0008), which is much more precise than the results of previous MR studies.
7.2 Blood lipids
For the lipid studies we use the 2010 GWAS reported by Teslovich et al. [50] to select instruments
and the 2013 GWAS (Metabochip data only) by the Global Lipids Genetics Consortium [51]. We
use two independent datasets, CAD and MI (UKB), to examine if the MR results replicate in two
studies. Because many SNPs are associated with more than one lipid traits, we also consider
the restricted sets of instruments that are not associated with the exposure being studied. For
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example, a restricted IV for HDL-C must be unassociated with LDL-C and TG (p-value > 0.5 in
the screening dataset). Our results for the blood lipids are reported in Table 5.
Similar to BMI, the results for LDL-C are highly significant and stable across different datasets
and sets of instruments. For CAD, in our most accurate result using all the unrestricted instruments,
the estimated odds ratio is 1.61 (95% CI 1.52–1.71). The CI is much shorter than previous MR
studies. The estimated odds ratio does not move by much when we use the restricted instruments:
1.6 (95% CI 1.38–1.86), though the CI becomes wider because fewer SNPs are used. Similar
observations are found when MI (UKB) is used as the outcome.
For HDL-C, the MR analyses using all the SNPs appears to suggest that HDL-C is protective.
For example, in the analysis using the CAD dataset and all the unrestricted instruments, the es-
timated odds ratio is 0.78 (95% CI 0.73–0.84). However, this highly significant result is mostly
driven by the weaker instruments. When using the SNPs that are not genome-wide significant in
HDL (2010) dataset, the estimated causal effect becomes weaker and not statistically significant
when using the restricted instruments or the MI (UKB) data. The diagnostic plots (Figures C2b,
C3b, C4b and C5b) also show strong evidence of heterogeneity between the strong and weak in-
struments.
For TG, the MR analyses using unrestricted instruments all yield statistically significant results.
When using the CAD dataset and all the unrestricted instruments, the estimated odds ratio is 1.29
(95% CI 1.2–1.38). However, our heterogeneity test shows strong evidence of heterogeneity. When
using the restricted instruments for both studies, the confidence intervals become very wide and
not statistically significant due to the lack of instruments that are exclusively associated with TG.
In conclusion, the potential causal role of triglycerides in CAD remains uncertain based on our
results.
8 Discussion
Our examples in Sections 6 and 7 demonstrate that a genome-wide MR design is usually much
more powerful than a MR analysis that just uses a small set of strong genetic instruments. The
empirical partially Bayes technique introduced in this paper can further increases the statistical
power.
Our empirical results reaffirm the causal effect of adiposity and LDL-C on the risk of coronary
artery disease. Additionally, our MR analysis gives strong support for the causal role of adiposity
in the development of ischemic stroke. Another observation is that in these cases the estimated
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Exposure: LDL-c Exposure: HDL-c Exposure: TG
Observational studies
Angelantonio et al. (2009) [57]
Adjust for non-lipid factors 1.56 (1.47, 1.66) 0.71 (0.68, 0.75) 1.37 (1.31, 1.42)
Also adjust for lipids 1.50 (1.39, 1.61) 0.78 (0.74, 0.82) 0.99 (0.94, 1.05)
Voight et al. (2012) [13] 1.54 (1.45, 1.63) 0.62 (0.58, 0.66) 1.42 (1.31, 1.52)
Previous MR studies
Voight et al. (2012) [13] 2.13 (1.69, 2.69) 0.93 (0.68, 1.26) Not reported
Holmes et al. (2014) [14]∗
Unrestricted instruments 1.78 (1.58, 2.01) 0.78 (0.69, 0.87) 1.27 (1.11, 1.45)
Restricted instruments (p > 0.01) 1.92 (1.68, 2.19) 0.96 (0.70, 1.31) 1.26 (1.00, 1.61)
White et al. (2016) [58]
MR-Egger 1.68 (1.51, 1.87) 0.95 (0.85, 1.06) 1.28 (1.13, 1.45)
Multivariable MR 1.50 (1.39, 1.63) 0.86 (0.78, 0.96) 1.38 (1.19, 1.59)
New MR analysis: Lipids-CAD (CARDIoGRAMplusC4D)
Unrestricted instruments
Using significant SNPs 1.61 (1.48, 1.75) 0.82 (0.71, 0.94) 1.24 (1.11, 1.38)
Using non-significant SNPs 1.52 (1.24, 1.86) 0.75 (0.65, 0.85) 2.09 (1.66, 2.66)
Using all SNPs 1.61 (1.52, 1.71) 0.78 (0.73, 0.84) 1.29 (1.2, 1.38)
p-value for heterogeneity 0.21 < 0.001 < 0.001
Restricted instruments (p > 0.5)
Using significant SNPs 1.57 (1.13, 2.18) 0.87 (0.72, 1.06) 0.83 (0.62, 1.11)
Using non-significant SNPs 1.65 (1.31, 2.07) 0.59 (0.46, 0.75) 1.59 (0.96, 2.62)
Using all SNPs 1.6 (1.38, 1.86) 0.73 (0.62, 0.86) 0.95 (0.73, 1.25)
p-value for heterogeneity 0.08 0.36 0.19
New MR analysis: Lipids-MI (UK BioBank)
Unrestricted instruments
Using significant SNPs 1.27% (1.04%, 1.49%) -0.43% (-0.96%, 0.10%) 0.72% (0.32%, 1.12%)
Using non-significant SNPs 1.06% (0.39%, 1.72%) -1.07% (-1.54%, -0.60%) 2.41% (1.61%, 3.21%)
Using all SNPs 1.24% (1.03%, 1.45%) -0.77% (-1.02%, -0.53%) 1.03% (0.77%, 1.28%)
p-value for heterogeneity 0.99 < 0.001 < 0.001
Restricted instruments (p > 0.5)
Using significant SNPs 1.37% (0.25%, 2.49%) -0.25% (-1.04%, 0.53%) 0.36% (-0.77%, 1.49%)
Using non-significant SNPs 1.49% (0.53%, 2.45%) -2.26% (-3.14%, -1.37%) 1.7% (-0.61%, 4.00%)
Using all SNPs 1.25% (0.63%, 1.88%) -1.28% (-1.88%, -0.67%) 0.51% (-0.55%, 1.57%)
p-value for heterogeneity 0.66 0.1 0.06
Table 5: Previous and new results of the effect of major blood lipids on coronary artery disease (or myocardial
infarction) risk. The numbers reported in the Angelantonio et al. (2009) study are hazard ratios, and the
numbers reported in the new MR analysis using UK BioBank are risk differences. All other numbers are
odds ratios. The prevalence of myocardial infarction in UK BioBank is 8288/360420 = 2.30%, so a risk
difference of 1% roughly corresponds to an odds ratio of 1.45. Statistically non-significant results are shown
in blue color.
∗ The original results for the Holmes et al. (2014 study) were reported per 1 mmol/L increase of LDL-c and
HDL-c and 1 log unit increase of TG. We transformed the results to per 1 SD increase using the following
approximate standard deviations: SD(LDL-c) = 1 mmol/L, SD(HDL-c) = 0.4 mmol/L, SD(Log TG) = 0.5.
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causal effects are very close across different strength of the instruments. The homogeneity of the
effect further adds evidence to these causal relationships.
In comparison, although our most powerful genome-wide MR analyses show that the effect of
HDL-C on CAD is highly significant, there is also strong evidence of effect heterogeneity. Indeed,
the statistical significance is mostly driven by the weak instruments. When used alone, the weak
instruments give very different effect estimates (with non-overlapping confidence intervals) than the
strong instruments. The role of HDL-C in cardiovascular disease has been heatedly debated in the
recent years following the failure of several highly anticipated clinical trials for the CETP inhibitors
[59, 60, 61]. Observational epidemiology studies have long suggested that HDL-C is inversely
associated with the risk of myocardial infarction [57, 62, 63]. However, the failed CETP trials and
previous MR studies [13, 30] have led to the broad conclusion that HDL-C is unlikely a causal agent
for atherosclerotic cardiovascular disease [64, 65], though some remain hopeful in the HDL function
hypothesis [65, 66, 67]. Our MR analyses suggest that the causal role of HDL-C remains uncertain
and the effect of HDL-C is heterogeneous using different instruments. Relatedly, Bulik-Sullivan et
al. (2015) [21] also observed statistical significant genetic correlation (computed across the whole
genome) between HDL-C and CAD (see also Figure 2). We think further investigations are needed
to demystify the strong observational and genetic associations between HDL-C and CAD.
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A Technical details
A.1 The empirical partially Bayes approach
We propose a new way of eliminating the nuisance parameters γ that can increase the power of
genome-wide MR studies when most IVs are very weak (i.e. γ are very close to 0). The key idea is to
view the errors-in-variables regression as a semiparametric problem: instead of treating the vector γ
as the nuisance parameter whose dimension grows as more SNPs are used, we treat the (empirical)
distribution of γ as the nuisance. This idea originates from the general solution given by Kiefer and
Wolfowitz [68] to the Neyman-Scott problem in which the observed data are modeled by a mixture
distribution. In principle, the statistical inference can be carried out by solving a nonparametric
maximum likelihood problem, but the numerical problem is often extremely challenging [69].
We will take an empirical partially Bayes approach introduced by Lindsay [29] which is numer-
ically feasible and still has several good theoretical properties. The approach is partially Bayes
because only the nuisance parameters are modeled by a prior distribution [70, 71]. It is empirical
Bayes because the prior distribution is estimated empirically using the observed data.
Consider the simplest scenario where α = 0 and derive the conditional score function [72].
When α = 0, the log-likelihood function of the data (γˆ, Γˆ) is given by
l(β,γ) =
p∏
j=1
lj(β, γj), where lj(β, γj) = −(γˆj − γj)
2
2σ2Xj
− (Γˆj − βγj)
2
2σ2Y j
.
Thus the score function of β in the j-th SNP is given by
Sj(β, γj) =
∂
∂β
lj(β, γj) =
γj(Γˆj − βγj)
σ2Y j
.
and a sufficient statistic of the nuisance parameter γj is
Wj(β) =
γˆj
σ2Xj
+
βΓˆj
σ2Y j
. (1)
When β is given, the maximum likelihood estimator (MLE) of γj is
γˆj,MLE(β) =
Wj(β)
1/σ2Xj + β
2/σ2Y j
.
The conditional score function is the residual of the score function Sj conditioning on Wj . After
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some algebra, we obtain
Cj(β, γj) = Sj(β, γj)− E
[
Sj(β, γj)|Wj(β)
]
=
γj(Γˆj − βγˆj)
β2σ2Xj + σ
2
Y j
. (2)
We would like to make three remarks on the conditional score (2). First, it is proportional to the
“regression residual” Γˆj − βγˆj which has mean 0 at the true β. Second, the nuisance parameter
appears in (2) only as a weight to the “regression residual”, as noticed by Lindsay [29]. Third, the
sufficient statistic Wj(β) of γj in (1) is independent of Γˆj−βγˆj because they are jointly normal and
their covariance is 0, regardless of what β is. See [73] for a related application of the conditional
score in measurement error models. These observations motivate the following estimating function
of β:
C(β) =
p∑
j=1
Cj
(
β, γˆj
(
β,Wj(β)
))
=
p∑
j=1
γˆj
(
β,Wj(β)
) · (Γˆj − βγˆj)
β2σ2Xj + σ
2
Y j
, (3)
where γˆj
(
β,Wj(β)
)
is any estimator of γˆj that only depends on the sufficient statistic Wj(β), not
necessarily the MLE. It is obvious that the estimating function is always unbiased, i.e. E[C(β)] = 0
at the true value of β, regardless of what form of γˆj is used. The estimator βˆ is obtained by solving
C(β) = 0.
The profile score approach [20] can be viewed as a special case of the conditional score, where
the “weights” are the MLE of γj : γˆj
(
β,Wj(β)
)
= γˆj,MLE(β). This is also equivalent to using a flat
prior in the partially Bayes approach that will be explained shortly. Under regularity conditions,
we prove in our previous article [20] that the profile score provides a consistent and asymptotically
normal estimator of β. However, this estimator is not efficient in general. To see this, let’s assume
most γj are equal to 0. Intuitively, the j-th IV provides no information on β because the distribution
of (γˆj , Γˆj) does not depend on β. However, some information is still used to estimate γj in the MLE,
resulting in a loss of statistical efficiency. This phenomenon is particularly relevant in genome-wide
MR as most of the genetic instruments are very weak.
When σ2Xj and σ
2
Y j are equal across j, Lindsay [29] points out that the efficient estimator of β
is given by the weight γˆ∗j = Epi∗ [γj |Wj(β)], where pi∗ is the empirical distribution of γ. However,
since γ and hence pi∗ is unknown, it is impossible to compute γˆ∗j directly. Lindsay proposes to use
the empirical Bayes (EB) estimator of γ. Suppose the distribution of γ is modeled by a parametric
family piη and ηˆ is an estimate of η using the observed data. We can use
γˆj,EB(β,Wj(β)) = Epiηˆ [γj |Wj(β)] (4)
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in the estimating function (3). Since this is usually a better estimator of the whole vector γ than
the MLE, a phenomenon known as the James-Stein paradox [74, 75], it is natural to expect that
the resulting function of β is also more efficient than the profile score. In fact, Lindsay [29] shows
that the estimator has a local efficiency property: when the parametric distribution piη is specified
correctly, the estimator βˆ is asymptotically efficient; when piη is specified incorrectly, the estimator
is not efficient but still consistent.
A.2 Implementation details
A.2.1 Spike-and-slab prior
Model (4.2) implies that γˆj/σXj also follows a Gaussian mixture distribution marginally:
γˆj/σXj
i.i.d.∼ p1 ·N(0, σ21 + 1) + (1− p1) ·N(0, σ22 + 1), j = 1, . . . , p. (5)
In practice we use maximum likelihood to estimate the prior parameters (p1, σ
2
1, σ
2
2) by fitting the
marginal mixture model (5) to the exposure z-statistics γˆj/σXj , j = 1, . . . , p.
The posterior mean of γi/σXi can be computed using the formulas in Proposition 1.
Proposition 1. Suppose Z ∼ N(γ, σ2), γ ∼ p1N(µ1, σ21) + (1 − p1)N(µ2, σ22), then γ|Z ∼ p˜ ·
N(µ˜1, σ˜
2
1) + (1− p˜) ·N(µ˜2, σ˜22), where
µ˜k =
Z/σ2 + µk/σ
2
k
1/σ2 + 1/σ2k
, σ˜2k =
1
1/σ2 + 1/σ2k
, and
p˜ =
p1 · ϕ(Z;µ1, σ2 + σ21)
p1 · ϕ(Z;µ1, σ2 + σ21) + (1− p1) · ϕ(Z;µ2, σ2 + σ22)
.
In the above equation, ϕ(z;µ, σ2) is the probability density function of the normal distribution
N(µ, σ2): ϕ(z;µ, σ2) = (
√
2piσ2)−1 exp{−(z − µ)2/(2σ2)}. The posterior mean of γ is given by
γˆ = E[γ|Z] = p˜µ˜1 + (1− p˜)µ˜2.
We want to make two remarks about the choice of prior distribution. First, there is an attractive
property of setting the means to be 0 in (4.2). Using Proposition 1, it is easy to verify that, when
µ1 = µ2 = 0, E[γ|Z] = −E[γ| − Z]. As a consequence, the estimating functions in (4.3) are
invariant to allele-recoding, meaning if a pair of observations (γˆj , Γˆj) is replaced by (−γˆj ,−Γˆj),
the point estimate βˆ is unchanged. This is desirable because the allele coding used in a GWAS
is often arbitrary. The second remark is that the spike-and-slab implementation is actually quite
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important in order to gain efficiency. To see this, suppose a single Gaussian prior is used (as in the
empirical Bayes interpretation of the James-Stein estimator). It is easy to show that every SNP
then receives the same amount of multiplicative shrinkage, so the first estimating function in (4.3)
is just scaled by a constant. As a consequence, the estimator βˆ is the same no matter how large
the shrinkage is. By using a spike-and-slab prior, every genetic instrument is shrunken selectively
[46] according to the its strength and thus efficiency might be gained. It is then natural to expect
that the efficiency gain is more substantial when the two components are more distant (σ1 and σ2
are more different). See Section 6 for an example.
In Figure A1 we examine the fit of the Gaussian mixture model (5) for our primary analysis of
HDL-c in Section 7. In this example we selected 1122 SNPs and the estimated prior parameters
are p1 = 0.91, σ1 = 0.73, σ2 = 4.57. In the left panel of Figure A1 we compare the empirical
distribution of γˆj/σXj (black histogram) with the fitted Gaussian mixture distribution in (5) (red
curve). We find the empirical fit is quite good. In the right panel of Figure A1 we plot the
empirical Bayes shrinkage estimator as a function of the z-score. When the z-score is close to
0, it is shrunken aggressively towards 0; when the z-score is large (e.g. greater than 5), there is
essentially no shrinkage.
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Figure A1: Examine the fitted prior distribution for HDL-C using 861 restricted SNPs used in
Table C3b. The left panel compares the empirical distribution of zj = γˆj/σXj (black histogram)
with the fitted Gaussian mixture distribution in (5) (red curve). The right panel shows the posterior
mean as a function of the z-score.
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A.2.2 Choice of robust score function
In our empirical analysis we will consider two choices of the function ψ(·). The first is the identity
function ψI(t) = t which is non-robust, and the second is the Huber score function [76] that is
robust:
ψH(t) =

t, if |t| ≤ k,
k · sign(t), otherwise.
The tuning constant k is chosen to be 1.345, which corresponds to 95% asymptotic efficiency
for normal samples in the standard location problem. Another common choice of the robust score
function is Tukey’s biweight [77], where large outliers essentially have no influence on the estimator.
In practice we find that using Tukey’s biweight usually gives more local roots than Huber’s score.
Thus we only report results of the more stable Huber’s score in the application.
A.2.3 Multiple roots of the estimating equations
In practice, the estimating functions in (4.3) may have multiple roots. Some roots are trivial: it is
straightforward to show that C˜(β, τ2)→ 0 if β → ±∞ or τ2 ±∞. These unbounded roots can be
easily ruled out. However, often there are multiple finite roots. When this happens, we report the
root whose βˆ is closest to the profile-likelihood estimator of β assuming all the SNPs are valid IVs
[20]. The latter is always unique because it solves an optimization problem. When there is another
root that is also close to the profile-likelihood estimator (the criterion we use in the application
is the absolute difference is no more than 5 times the closest difference), we report the empirical
partially Bayes estimator is not available.
A.2.4 Standard error of the estimator
Our final problem is to compute the standard error of the estimator θˆ = (βˆ, τˆ2). For the calculation
below we assume all SNPs satisfy αj ∼ N(0, τ2), i.e. there is no outlier. After taking a first-order
Taylor expansion at the true value of θ = (β, τ2),
0 = C˜(θˆ) ≈ C˜(θ) +∇C˜(θ) · (θˆ − θ),
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the variance of θˆ can be approximated using the Delta method by
Var(θˆ) ≈
[
∇C˜(θ)
]−1
Var
(
C˜(θ)
) [
∇C˜(θ)
]−T
.
By repeatedly using the fact that γˆj,EB is independent of tj(β, τ
2) (so several terms have mean 0
and are dismissed), we obtain, after some algebra, that
Var
(
C˜(θ)
)
≈
p∑
j=1
c1γˆ2j
/
s2j 0
0 c2γˆ
2
j
/
s4j
 , and
∇C˜(θ) ≈
p∑
j=1

[
ψ1(tj) · (∂/∂β)γˆj + γˆjψ′1(tj) · (∂/∂β)tj
]
/sj
[
ψ1(tj) · (∂/∂τ2)γˆj
]
/sj
0 (δ + c3)/(2s
4
j )
 .
(6)
The subscript EB and the dependence of sj and tj on θ are suppressed to simplify the expressions.
The constants appeared in (6) are δ = E[ψ2(Z)], c1 = E[ψ21(Z)], c2 = Var(ψ2(Z)), c3 = E[Zψ′(Z)−
ψ(Z)] for Z ∼ N(0, 1). Assuming θˆ is a good estimator of θ, the matrices in (6) can be estimated
by replacing θ with θˆ.
A.2.5 Diagnostics
To check the modeling assumptions we propose to use a scatterplot of standardized residuals
tj(βˆ, τˆ
2) versus the empirical Bayes estimates γˆj,EB(βˆ, τˆ
2), j = 1, . . . , p. Note that both tj and
γˆj,EB depend on the allele coding. To ease the visualization, we choose the allele coding such that
γˆj,EB is positive. Under our modeling assumptions, if (βˆ, τˆ
2) is close to the true value, most of
tj(βˆ, τˆ
2) should be independent of γˆj,EB(βˆ, τˆ
2) and distributed like a standard normal. We can
verify this implication by computing a smoothing spline of the scatter-plot and check it is different
from the x-axis (constant 0). More specifically, we run a linear regression with B-splines of tj(βˆ, τˆ
2)
with degrees of freedom bp/50c and report the F -test result as “heterogeneity p-value”. We also
use the Q-Q plot of tj(βˆ, τˆ
2) against standard normal to check if there is excessive pleiotropy that
could not be explained by the normal random effects model.
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B Data availability
BMI (Jap): GWAS summary dataset is downloaded from ftp://ftp.ebi.ac.uk/pub/databases/
gwas/summary_statistics/AkiyamaM_28892062_GCST004904.
BMI (UKB) and MI (UKB): Round 2 GWAS summary results for the UK BioBank data are
available at http://www.nealelab.is/uk-biobank/.
LDL-C (2010), HDL-C (2010), and TG (2010): GWAS summary dataset is downloaded from
http://csg.sph.umich.edu/willer/public/lipids2010/.
LDL-C (2010), HDL-C (2010), and TG (2010): GWAS summary results for the Metabochip
data are downloaded from http://csg.sph.umich.edu/willer/public/lipids2013/.
CAD: GWAS summary dataset is downloaded from the CARDIoGRAMplusC4D Consortium web-
site: http://www.cardiogramplusc4d.org/data-downloads/.
IS: GWAS summary results for the European samples are downloaded from ftp://ftp.ebi.ac.
uk/pub/databases/gwas/summary_statistics/MalikR_29531354_GCST005843.
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C Detailed results
C.1 Results
In Tables C1 to C5, we report detailed results of our MR analyses.
psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 1119 44 1075
p1 0.84 0.81 0.52
σ1 1.41 6.55 0.69
σ2 5.57 14.22 2.82
MR-Egger 0.386 (0.077) 0.513 (0.184) 0.442 (0.105)
Wtd. Med. 0.284 (0.1) 0.278 (0.124) 0.348 (0.105)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0,ψI 0.382 (0.061) 0.388 (0.06) 0.291 (0.086) 0.292 (0.086) 0.447 (0.084) 0.454 (0.082)
τ2 = 0,ψH 0.398 (0.061) 0.401 (0.061) 0.345 (0.088) 0.346 (0.088) 0.446 (0.084) 0.452 (0.083)
τ2 6= 0,ψI 0.367 (0.067) 0.374 (0.066) 0.297 (0.12) 0.298 (0.12) 0.418 (0.09) 0.427 (0.089)
τ2 6= 0,ψH 0.382 (0.068) 0.387 (0.068) 0.332 (0.117) 0.332 (0.117) 0.42 (0.092) 0.426 (0.091)
(a) Screening: BMI (Dataset: Akiyama et al. (2017)); Exposure: BMI (Dataset: UK BioBank); Outcome:
CAD, (Dataset: CARDIoGRAMplusC4D).
psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 1880 63 1817
p1 0.88 0.81 0.77
σ1 1.2 5.38 0.94
σ2 5.35 13.05 3.07
MR-Egger 0.13 (0.056) 0.193 (0.122) 0.101 (0.076)
Wtd. Med. 0.112 (0.094) 0.11 (0.107) 0.205 (0.087)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0,ψI 0.149 (0.05) 0.157 (0.049) 0.157 (0.071) 0.156 (0.071) 0.144 (0.069) 0.154 (0.068)
τ2 = 0,ψH 0.166 (0.051) 0.177 (0.05) 0.176 (0.073) 0.175 (0.073) 0.158 (0.07) 0.175 (0.069)
τ2 6= 0,ψI 0.148 (0.051) 0.156 (0.051) 0.157 (0.083) 0.157 (0.083) 0.142 (0.07) 0.152 (0.069)
τ2 6= 0,ψH 0.163 (0.053) 0.174 (0.052) 0.177 (0.082) 0.176 (0.082) 0.153 (0.072) 0.169 (0.071)
(b) Screening: BMI (Dataset: Akiyama et al. (2017)); Exposure: BMI (Dataset: UK BioBank); Outcome:
IS (Dataset: Malik et al. (2018)).
Table C1: Comparison of different MR methods to estimate the effects of Body Mass Index (BMI)
on Coronary Artery Disease (CAD) and ischemic stroke (IS).
37
psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 1214 37 1177
p1 0.92 0.99 0.85
σ1 0.54 10.87 0.34
σ2 7.32 10.87 2.08
MR-Egger 0.3909 (0.0316) 0.5047 (0.0877) 0.0565 (0.0644)
Wtd. Med. 0.4215 (0.0486) 0.4872 (0.0476) 0.1825 (0.0699)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0,ψI 0.475 (0.031) 0.479 (0.029) 0.473 (0.029) 0.473 (0.029) 0.489 (0.164) 0.535 (0.134)
τ2 = 0,ψH 0.499 (0.031) 0.497 (0.028) 0.49 (0.029) 0.49 (0.029) 0.562 (0.126) 0.567 (0.106)
τ2 6= 0,ψI 0.424 (0.033) 0.449 (0.032) 0.445 (0.047) 0.445 (0.047) 0.259 (0.109) 0.329 (0.116)
τ2 6= 0,ψH 0.458 (0.033) 0.477 (0.031) 0.476 (0.043) 0.476 (0.043) 0.345 (0.11) 0.42 (0.102)
(a) Screening: LDL-C (Dataset: Teslovich et al. (2010)); Exposure: LDL-C (Dataset: Metabochip, Willer
et al. (2013)); Outcome: CAD, (Dataset: CARDIoGRAMplusC4D).
psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 1191 42 1149
p1 0.89 0.01 0.86
σ1 0.72 8.94 0.61
σ2 5.75 8.94 2.82
MR-Egger -0.172 (0.0364) 0.1911 (0.1138) -0.2896 (0.0597)
Wtd. Med. 0.0111 (0.056) 0.0461 (0.0691) -0.0824 (0.0615)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0,ψI -0.25 (0.034) -0.212 (0.032) -0.151 (0.035) -0.151 (0.035) -0.479 (0.078) -0.421 (0.07)
τ2 = 0,ψH -0.325 (0.033) -0.275 (0.031) -0.238 (0.035) -0.238 (0.035) -0.431 (0.071) -0.349 (0.065)
τ2 6= 0,ψI -0.229 (0.037) -0.201 (0.036) -0.171 (0.069) -0.171 (0.069) -0.383 (0.073) -0.35 (0.069)
τ2 6= 0,ψH -0.282 (0.036) -0.245 (0.035) -0.201 (0.07) -0.201 (0.07) -0.353 (0.072) -0.294 (0.067)
(b) Screening: HDL-C (Dataset: Teslovich et al. (2010)); Exposure: HDL-C (Dataset: Metabochip, Willer
et al. (2013)); Outcome: CAD, (Dataset: CARDIoGRAMplusC4D).
psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 1194 28 1166
p1 0.95 0.01 0.83
σ1 0.61 11.48 0.27
σ2 8.21 11.48 1.93
MR-Egger 0.2037 (0.0355) 0.0881 (0.0865) 0.2767 (0.0761)
Wtd. Med. 0.1784 (0.054) 0.1761 (0.0511) 0.219 (0.0815)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0,ψI 0.313 (0.036) 0.261 (0.032) 0.202 (0.032) 0.202 (0.032) 1.179 (0.19) 1.039 (0.181)
τ2 = 0,ψH 0.344 (0.035) 0.268 (0.032) 0.213 (0.033) 0.213 (0.033) 1.091 (0.156) 0.987 (0.134)
τ2 6= 0,ψI 0.277 (0.038) 0.248 (0.036) 0.217 (0.051) 0.217 (0.051) 0.7 (0.144) 0.709 (0.127)
τ2 6= 0,ψH 0.288 (0.038) 0.255 (0.036) 0.217 (0.055) 0.217 (0.055) 0.726 (0.145) 0.735 (0.125)
(c) Screening: TG (Dataset: Teslovich et al. (2010)); Exposure: TG (Dataset: Metabochip, Willer et al.
(2013)); Outcome: CAD, (Dataset: CARDIoGRAMplusC4D).
Table C2: Comparison of different MR methods to estimate the effects of blood lipid levels on
Coronary Artery Disease (CAD) using the CARDIoGRAMplusC4D dataset and unrestricted in-
struments.
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psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 898 11 887
p1 0.92 0.01 0.92
σ1 0.47 5.93 0.44
σ2 3.38 5.93 2.39
MR-Egger 0.3167 (0.0614) 0.7336 (0.3916) 0.2563 (0.0731)
Wtd. Med. 0.3027 (0.0821) 0.4638 (0.1241) 0.2291 (0.0786)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0,ψI 0.432 (0.089) 0.504 (0.081) 0.419 (0.101) 0.419 (0.101) 0.443 (0.135) 0.577 (0.13)
τ2 = 0,ψH 0.364 (0.085) 0.483 (0.076) 0.44 (0.098) 0.44 (0.098) 0.29 (0.126) 0.514 (0.116)
τ2 6= 0,ψI 0.393 (0.086) 0.482 (0.08) 0.449 (0.167) 0.449 (0.167) 0.395 (0.128) 0.538 (0.123)
τ2 6= 0,ψH 0.348 (0.085) 0.471 (0.077) 0.452 (0.167) 0.452 (0.167) 0.277 (0.126) 0.498 (0.116)
(a) Screening: LDL-C (Dataset: Teslovich et al. (2010)); Exposure: LDL-C (Dataset: Metabochip, Willer
et al. (2013)); Outcome: CAD, (Dataset: CARDIoGRAMplusC4D).
psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 869 8 861
p1 0.95 0.01 0.93
σ1 0.68 7.07 0.65
σ2 3.88 7.07 2.38
MR-Egger -0.0757 (0.0704) -0.1905 (0.3977) -0.057 (0.0839)
Wtd. Med. -0.1496 (0.0812) -0.0792 (0.1235) -0.1836 (0.0861)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0,ψI -0.402 (0.107) -0.377 (0.086) -0.142 (0.097) -0.142 (0.097) -0.622 (0.182) -0.676 (0.155)
τ2 = 0,ψH -0.419 (0.094) -0.38 (0.081) -0.139 (0.1) -0.139 (0.1) -0.651 (0.143) -0.707 (0.13)
τ2 6= 0,ψI -0.276 (0.093) -0.296 (0.085) -0.142 (0.097) -0.142 (0.097) -0.348 (0.13) -0.43 (0.124)
τ2 6= 0,ψH -0.318 (0.092) -0.318 (0.085) -0.139 (0.1) -0.139 (0.1) -0.447 (0.131) -0.53 (0.125)
(b) Screening: HDL-C (Dataset: Teslovich et al. (2010)); Exposure: HDL-C (Dataset: Metabochip, Willer
et al. (2013)); Outcome: CAD, (Dataset: CARDIoGRAMplusC4D).
psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 881 2 879
p1 0.99 0.01 0.98
σ1 0.4 8.3 0.38
σ2 4.58 8.3 2.49
MR-Egger 0.0787 (0.0822) -0.1803 (0.1427) 0.1616 (0.0935)
Wtd. Med. -0.0195 (0.1264) -0.1803 (0.1427) 0.1299 (0.0948)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0,ψI 0.207 (0.259) 0.046 (0.136) -0.182 (0.144) -0.182 (0.144) 0.886 (0.657) 0.852 (0.374)
τ2 = 0,ψH 0.25 (0.225) -0.064 (0.132) -0.182 (0.148) -0.182 (0.148) 0.77 (0.46) 0.972 (0.333)
τ2 6= 0,ψI 0.142 (0.187) 0.044 (0.136) -0.182 (0.144) -0.182 (0.144) 0.381 (0.307) 0.555 (0.255)
τ2 6= 0,ψH 0.159 (0.192) -0.047 (0.136) -0.182 (0.148) -0.182 (0.148) 0.385 (0.315) 0.464 (0.256)
(c) Screening: TG (Dataset: Teslovich et al. (2010)); Exposure: TG (Dataset: Metabochip, Willer et al.
(2013)); Outcome: CAD, (Dataset: CARDIoGRAMplusC4D).
Table C3: Comparison of different MR methods to estimate the effects of blood lipid levels on
Coronary Artery Disease (CAD) using the CARDIoGRAMplusC4D dataset and restricted instru-
ments.
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psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 1140 37 1103
p1 0.92 0.99 0.87
σ1 0.55 10.87 0.4
σ2 7.27 10.87 2.34
MR-Egger 0.011 (0.0011) 0.0127 (0.0023) 0.0047 (0.0024)
Wtd. Med. 0.0122 (0.0017) 0.0124 (0.0016) 0.0061 (0.0027)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0,ψI 0.012 (0.001) 0.012 (0.001) 0.012 (0.001) 0.012 (0.001) 0.014 (0.005) 0.013 (0.004)
τ2 = 0,ψH 0.013 (0.001) 0.013 (0.001) 0.013 (0.001) 0.013 (0.001) 0.015 (0.004) 0.014 (0.003)
τ2 6= 0,ψI 0.012 (0.001) 0.012 (0.001) 0.012 (0.001) 0.012 (0.001) 0.01 (0.004) 0.01 (0.003)
τ2 6= 0,ψH 0.012 (0.001) 0.012 (0.001) 0.013 (0.001) 0.013 (0.001) 0.01 (0.004) 0.011 (0.003)
(a) Screening: LDL-C (Dataset: Teslovich et al. (2010)); Exposure: LDL-C (Dataset: Metabochip, Willer
et al. (2013)); Outcome: CAD, (Dataset: UK BioBank).
psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 1079 39 1040
p1 0.89 0.01 0.85
σ1 0.76 9.15 0.64
σ2 5.9 9.15 2.81
MR-Egger -0.0056 (0.0013) 0.0094 (0.0043) -0.0112 (0.0022)
Wtd. Med. -0.0018 (0.0019) -7e-04 (0.0025) -0.0044 (0.0024)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0,ψI -0.007 (0.001) -0.007 (0.001) -0.004 (0.001) -0.004 (0.001) -0.014 (0.003) -0.014 (0.002)
τ2 = 0,ψH -0.009 (0.001) -0.008 (0.001) -0.006 (0.001) -0.006 (0.001) -0.012 (0.003) -0.011 (0.002)
τ2 6= 0,ψI -0.007 (0.001) -0.006 (0.001) -0.004 (0.003) -0.004 (0.003) -0.013 (0.003) -0.014 (0.002)
τ2 6= 0,ψH -0.009 (0.001) -0.008 (0.001) -0.004 (0.003) -0.004 (0.003) -0.011 (0.003) -0.011 (0.002)
(b) Screening: HDL-C (Dataset: Teslovich et al. (2010)); Exposure: HDL-C (Dataset: Metabochip, Willer
et al. (2013)); Outcome: CAD, (Dataset: UK BioBank).
psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 1122 27 1095
p1 0.95 0.01 0.84
σ1 0.64 11.68 0.34
σ2 8.26 11.68 1.99
MR-Egger 0.0088 (0.0013) 0.0032 (0.0035) 0.0139 (0.0027)
Wtd. Med. 0.0072 (0.0019) 0.0072 (0.0018) 0.0087 (0.003)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0,ψI 0.013 (0.001) 0.011 (0.001) 0.008 (0.001) 0.008 (0.001) 0.033 (0.005) 0.03 (0.004)
τ2 = 0,ψH 0.013 (0.001) 0.011 (0.001) 0.008 (0.001) 0.008 (0.001) 0.03 (0.004) 0.026 (0.004)
τ2 6= 0,ψI 0.012 (0.001) 0.01 (0.001) 0.007 (0.002) 0.007 (0.002) 0.029 (0.005) 0.027 (0.004)
τ2 6= 0,ψH 0.012 (0.001) 0.01 (0.001) 0.007 (0.002) 0.007 (0.002) 0.027 (0.005) 0.024 (0.004)
(c) Screening: TG (Dataset: Teslovich et al. (2010)); Exposure: TG (Dataset: Metabochip, Willer et al.
(2013)); Outcome: CAD, (Dataset: UK BioBank).
Table C4: Comparison of different MR methods to estimate the effects of blood lipid levels on
Coronary Artery Disease (CAD) using the UK BioBank dataset and unrestricted instruments.
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psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 835 11 824
p1 0.92 0.01 0.92
σ1 0.45 5.93 0.42
σ2 3.41 5.93 2.41
MR-Egger 0.0108 (0.0025) 0.0165 (0.0132) 0.0095 (0.0029)
Wtd. Med. 0.006 (0.0033) 0.0068 (0.0049) 0.0067 (0.0033)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0,ψI 0.015 (0.004) 0.014 (0.003) 0.013 (0.004) 0.013 (0.004) 0.018 (0.006) 0.016 (0.006)
τ2 = 0,ψH 0.015 (0.004) 0.013 (0.003) 0.012 (0.004) 0.012 (0.004) 0.018 (0.006) 0.017 (0.005)
τ2 6= 0,ψI 0.014 (0.004) 0.014 (0.003) 0.014 (0.006) 0.014 (0.006) 0.015 (0.006) 0.015 (0.005)
τ2 6= 0,ψH 0.013 (0.004) 0.013 (0.003) 0.014 (0.006) 0.014 (0.006) 0.015 (0.005) 0.015 (0.005)
(a) Screening: LDL-C (Dataset: Teslovich et al. (2010)); Exposure: LDL-C (Dataset: Metabochip, Willer
et al. (2013)); Outcome: CAD, (Dataset: UK BioBank).
psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 800 7 793
p1 0.95 0.01 0.95
σ1 0.68 7.09 0.66
σ2 3.99 7.09 2.59
MR-Egger -0.0054 (0.0025) 0.0088 (0.0157) -0.0077 (0.003)
Wtd. Med. -0.0065 (0.0032) -0.0055 (0.005) -0.0084 (0.0034)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0,ψI -0.012 (0.003) -0.011 (0.003) -0.001 (0.004) -0.001 (0.004) -0.018 (0.005) -0.021 (0.004)
τ2 = 0,ψH -0.015 (0.003) -0.013 (0.003) -0.003 (0.004) -0.003 (0.004) -0.022 (0.005) -0.024 (0.004)
τ2 6= 0,ψI -0.011 (0.003) -0.011 (0.003) -0.001 (0.004) -0.001 (0.004) -0.017 (0.005) -0.02 (0.004)
τ2 6= 0,ψH -0.014 (0.003) -0.013 (0.003) -0.003 (0.004) -0.003 (0.004) -0.02 (0.005) -0.023 (0.005)
(b) Screening: HDL-C (Dataset: Teslovich et al. (2010)); Exposure: HDL-C (Dataset: Metabochip, Willer
et al. (2013)); Outcome: CAD, (Dataset: UK BioBank).
psel ∈ (0, 1) psel ∈ (0, 5× 10−8) psel ∈ (5× 10−8, 1)
# SNPs 801 2 799
p1 0.99 0.01 0.95
σ1 0.4 8.3 0.32
σ2 4.4 8.3 1.61
MR-Egger 0.0059 (0.0033) 0.0036 (0.0056) 0.0068 (0.0038)
Wtd. Med. 0.0064 (0.0042) 0.0036 (0.0056) 0.0043 (0.0039)
MLE Shrinkage MLE Shrinkage MLE Shrinkage
τ2 = 0,ψI 0.026 (0.009) 0.007 (0.005) 0.004 (0.006) 0.004 (0.006) 0.046 (0.016) 0.025 (0.017)
τ2 = 0,ψH 0.032 (0.009) 0.005 (0.005) 0.004 (0.006) 0.004 (0.006) 0.049 (0.017) 0.03 (0.015)
τ2 6= 0,ψI 0.021 (0.007) 0.006 (0.005) 0.004 (0.006) 0.004 (0.006) 0.033 (0.013) 0.018 (0.011)
τ2 6= 0,ψH 0.019 (0.008) 0.005 (0.005) 0.004 (0.006) 0.004 (0.006) 0.03 (0.014) 0.017 (0.012)
(c) Screening: TG (Dataset: Teslovich et al. (2010)); Exposure: TG (Dataset: Metabochip, Willer et al.
(2013)); Outcome: CAD, (Dataset: UK BioBank).
Table C5: Comparison of different MR methods to estimate the effects of blood lipid levels on
Coronary Artery Disease (CAD) using the UK BioBank dataset and restricted instruments.
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C.2 Diagnostic plots
Figures C1 to C5 below are diagnostic plots to check instrument heterogeneity. If our modeling
assumptions are satisfied, most of the standardized residuals (y-axis) should be approximately
independent of the instrument weight (x-axis), checked by the scatter-plot in the left panel of each
figure, and should roughly follow the standard normal distribution, checked by the quantile-quantile
plot in the right panel of each figure. The heterogeneity p-values are computed by testing the null
model in the linear regression of the standardized residual on the absolute weight (expanded using
B-splines with degrees of freedom equal to #instruments/20).
Estimated effect: 0.38
Heterogeneity p−value: 0.79
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Heterogeneity p−value: 0.82
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(a) Screening: BMI (Dataset: Akiyama et al. (2017)); Exposure: BMI (Dataset: UK BioBank); Outcome:
CAD, (Dataset: CARDIoGRAMplusC4D).
Estimated effect: 0.16
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(b) Screening: BMI (Dataset: Akiyama et al. (2017)); Exposure: BMI (Dataset: UK BioBank); Outcome:
IS (Dataset: Malik et al. (2018)).
Figure C1: Diagnostic plots for the BMI results.
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Estimated effect: 0.46Heterogeneity p−value: 0.21
Estimated effect: 0.48Heterogeneity p−value: 0.28
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(a) LDL-c.
Estimated effect: −0.23
Heterogeneity p−value: 0.00018
Estimated effect: −0.19
Heterogeneity p−value: 2.9e−05
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(b) HDL-c.
Estimated effect: 0.29
Heterogeneity p−value: 0.0096
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(c) TG.
Figure C2: Diagnostic plots for the lipids results using unrestricted instruments and the CARDIo-
GRAMplusC4D dataset.
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Estimated effect: 0.35
Heterogeneity p−value: 0.083
Estimated effect: 0.47
Heterogeneity p−value: 0.58
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(a) LDL-c.
Estimated effect: −0.32
Heterogeneity p−value: 0.36
Estimated effect: −0.32
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Figure C3: Diagnostic plots for the lipids results using restricted instruments and the CARDIo-
GRAMplusC4D dataset.
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Figure C4: Diagnostic plots for the lipids results using unrestricted instruments and the UK
BioBank dataset dataset.
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Figure C5: Diagnostic plots for the lipids results using restricted instruments and the UK BioBank
dataset.
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